Headlines about Xenon Pharmaceuticals (NASDAQ:XENE) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.7228712921991 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of equities analysts recently weighed in on XENE shares. Jefferies Group LLC set a $5.00 price target on Xenon Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 4th. Zacks Investment Research upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st.
Shares of Xenon Pharmaceuticals (XENE) traded up $0.20 during midday trading on Monday, reaching $2.40. The company’s stock had a trading volume of 521,400 shares, compared to its average volume of 93,559. Xenon Pharmaceuticals has a 12-month low of $2.10 and a 12-month high of $9.95.
In other news, Director Mohammad Azab purchased 15,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was bought at an average cost of $2.22 per share, with a total value of $33,300.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 9.40% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Xenon Pharmaceuticals (XENE) Stock Price” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/20/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-xenon-pharmaceuticals-xene-stock-price.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.